Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease
Phase 1
- Conditions
- neuroinflammatory disorder, Parkinson's disease, Brain tumor
- Registration Number
- JPRN-UMIN000030084
- Lead Sponsor
- Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
i) Having communication disorder ii) In severe general condition iii) Having severe infection or other severe complications iv) Having severe drug allergy v) Having difficulty in expression of consent vi) Pregnancy or possible pregnancy. During breast feed vii) Judged as inappropriate by doctors for other reasons in case of [18F]-GE180, [18F]-FLT viii) Surgical history on the site of the disease, which causes possible false-positive signal in case of [18F]-FDOPA ix) Difficulty in withdrawal of listed medication for Parkinson's disease due to medical reasons or dissent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FLT PET detects malignant brain tumors. F-dopa PET detects dopamine neurons in healthy brains and decreased signal in Parkinsonian brains. GE180 PET detects neuroinflammatory disorders.
- Secondary Outcome Measures
Name Time Method Safety of the PET studies with three tracers is assessed.